PReS-FINAL-2166: Long-term safety and effectiveness of anti-interleukin-6 receptor monoclonal antibody, tocilizumab, in patients with systemic juvenile idiopathic arthritis in Japan

S Yokota; T Nozawa; T Kanetaka; K Yamazaki; T Sato; N Sakurai; M Kikuchi

首页> 外文期刊>Pediatric rheumatology online journal >PReS-FINAL-2166: Long-term safety and effectiveness of anti-interleukin-6 receptor monoclonal antibody, tocilizumab, in patients with systemic juvenile idiopathic arthritis in Japan

【24h】

PReS-FINAL-2166: Long-term safety and effectiveness of anti-interleukin-6 receptor monoclonal antibody, tocilizumab, in patients with systemic juvenile idiopathic arthritis in Japan

机译：PReS-FINAL-2166：抗白细胞介素6受体单克隆抗体托西珠单抗在日本系统性幼年特发性关节炎患者中的长期安全性和有效性

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Pediatric rheumatology online journal》 |2013年第s2期|共页
作者
S Yokota; T Nozawa; T Kanetaka; K Yamazaki; T Sato; N Sakurai; M Kikuchi;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类小儿内科学;
关键词

相似文献

外文文献
中文文献
专利

1. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan [J] . YokotaS., ImagawaT., MoriM., The Journal of rheumatology . 2014,第4期

机译：抗白细胞介素6受体单克隆抗体tocilizumab在系统性幼年特发性关节炎患者中的长期安全性和有效性
2. Improvement of reduced serum cartilage oligomeric matrix protein levels in systemic juvenile idiopathic arthritis patients treated with the anti-interleukin-6 receptor monoclonal antibody tocilizumab [J] . Shoko Nakajima, Takuya Naruto, Takako Miyamae, Modern Rheumatology . 2009,第1期

机译：抗白介素6受体单克隆抗体妥珠单抗治疗的系统性幼年特发性关节炎患者血清软骨寡聚基质蛋白水平降低的改善
3. Improvement of reduced serum cartilage oligomeric matrix protein levels in systemic juvenile idiopathic arthritis patients treated with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. [J] . Nakajima S, Naruto T, Miyamae T, Modern rheumatology . 2009,第1期

机译：使用抗白介素6受体单克隆抗体tocilizumab治疗的系统性幼年特发性关节炎患者的血清软骨寡聚基质蛋白水平降低的改善。
4. THE INHIBITORY Fcy-RECEPTOR MB (CD32B) IS HIGHLY EXPRESSED ON CLONAL PLASMA CELLS FROM PATIENTS WITH SYSTEMIC LIGHT-CHAIN (AL) AMYLOIDOSIS AND PROVIDES A TARGET FOR MONOCLONAL ANTIBODY THERAPY [C] . P. Zhou, A B Olshen, E Bonvini, International Symposium on Amyloidosis . 2008

机译：抑制性FCY-受体MB（CD32B）对来自全身轻链（AL）淀粉样蛋白症患者的克隆血浆细胞高度表达，并为单克隆抗体治疗提供靶标
5. Real-world Effectiveness of Biologic Therapies in Children and Adults with Juvenile Idiopathic Arthritis in the United Kingdom [D] . Kearsley-Fleet, Lianne. 2019

机译：英国青少年特发性关节炎儿童和成人生物疗法的现实世界效力
6. PReS-FINAL-2166: Long-term safety and effectiveness of anti-interleukin-6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan [O] . S Yokota, T Nozawa, T Kanetaka, 2013

机译：PReS-FINAL-2166：抗白细胞介素6受体单克隆抗体托西珠单抗在日本系统性幼年特发性关节炎患者中的长期安全性和有效性
7. PReS-FINAL-2166: Long-term safety and effectiveness of anti-interleukin-6 receptor monoclonal antibody, tocilizumab, in patients with systemic juvenile idiopathic arthritis in Japan [O] . S Yokota, T Nozawa, T Kanetaka, 2013

机译：PReS-FINAL-2166：抗白介素6受体单克隆抗体托西珠单抗在日本系统性幼年特发性关节炎患者中的长期安全性和有效性

PReS-FINAL-2166: Long-term safety and effectiveness of anti-interleukin-6 receptor monoclonal antibody, tocilizumab, in patients with systemic juvenile idiopathic arthritis in Japan

著录项

相似文献

相关主题

期刊订阅